Trial · NCT00853762
Results by group252
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 252
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Injection Site Reactions, Infections, and Malignancies by Severity | Atacicept 25 mg (With Loading) | Mild TEAEs | 5 | Subjects | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Injection Site Reactions, Infections, and Malignancies by Severity | Atacicept 75 mg (With Loading) | Mild TEAEs | 8 | Subjects | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Injection Site Reactions, Infections, and Malignancies by Severity | Atacicept 150 mg (With Loading) | Mild TEAEs | 8 | Subjects | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Injection Site Reactions, Infections, and Malignancies by Severity | Atacicept 150 mg (Without Loading) | Mild TEAEs | 13 | Subjects | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Injection Site Reactions, Infections, and Malignancies by Severity | Atacicept 25 mg (With Loading) | Moderate TEAEs | 2 | Subjects | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Injection Site Reactions, Infections, and Malignancies by Severity | Atacicept 75 mg (With Loading) | Moderate TEAEs | 4 | Subjects | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Injection Site Reactions, Infections, and Malignancies by Severity | Atacicept 150 mg (With Loading) | Moderate TEAEs | 6 | Subjects | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Injection Site Reactions, Infections, and Malignancies by Severity | Atacicept 150 mg (Without Loading) | Moderate TEAEs | 4 | Subjects | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Injection Site Reactions, Infections, and Malignancies by Severity | Atacicept 25 mg (With Loading) | Severe TEAEs | 0 | Subjects | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Injection Site Reactions, Infections, and Malignancies by Severity | Atacicept 75 mg (With Loading) | Severe TEAEs | 0 | Subjects | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Injection Site Reactions, Infections, and Malignancies by Severity | Atacicept 150 mg (With Loading) | Severe TEAEs | 0 | Subjects | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Injection Site Reactions, Infections, and Malignancies by Severity | Atacicept 150 mg (Without Loading) | Severe TEAEs | 1 | Subjects | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Injection Site Reactions, Infections, and Malignancies by Severity | Atacicept 25 mg (With Loading) | Mild serious TEAEs | 0 | Subjects | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Injection Site Reactions, Infections, and Malignancies by Severity | Atacicept 75 mg (With Loading) | Mild serious TEAEs | 0 | Subjects | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Injection Site Reactions, Infections, and Malignancies by Severity | Atacicept 150 mg (With Loading) | Mild serious TEAEs | 0 | Subjects | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Injection Site Reactions, Infections, and Malignancies by Severity | Atacicept 150 mg (Without Loading) | Mild serious TEAEs | 0 | Subjects | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Injection Site Reactions, Infections, and Malignancies by Severity | Atacicept 25 mg (With Loading) | Moderate serious TEAEs | 0 | Subjects | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Injection Site Reactions, Infections, and Malignancies by Severity | Atacicept 75 mg (With Loading) | Moderate serious TEAEs | 1 | Subjects | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Injection Site Reactions, Infections, and Malignancies by Severity | Atacicept 150 mg (With Loading) | Moderate serious TEAEs | 0 | Subjects | |
| Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Injection Site Reactions, Infections, and Malignancies by Severity | Atacicept 150 mg (Without Loading) | Moderate serious TEAEs | 0 | Subjects |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00853762/results